key: cord-0992371-k2plxi63
authors: Duke, Heather; Posch, Liana; Green, Lauren
title: Axillary adenopathy following COVID-19 vaccination: A single institution case series
date: 2021-06-01
journal: Clin Imaging
DOI: 10.1016/j.clinimag.2021.05.023
sha: 643cde0c08439583de9cacf2197f349297a145c1
doc_id: 992371
cord_uid: k2plxi63

Axillary adenopathy is a potential side effect following COVID-19 vaccination. We report four cases of axillary adenopathy in the setting of recent COVID-19 vaccination (Moderna and Pfizer-BioNTech) at our institution. Our cases show unilateral axillary adenopathy, as well as adenopathy persisting for two to three weeks following vaccination. The Society of Breast Imaging (SBI) and Harvard University have each released guidelines for management of axillary adenopathy following COVID-19 vaccination. While SBI recommends short term imaging 4–12 weeks following the second dose, a group of physicians from Harvard suggest clinical follow-up with sonographic imaging if clinical concern persists beyond six weeks. As a larger percentage of the general population becomes vaccinated, it is important for radiologists to be aware of potential vaccine-induced ipsilateral axillary adenopathy on screening and diagnostic breast imaging to reduce the number of unnecessary biopsies performed in this patient population.

As COVID-19 was declared a global pandemic in March 2020 by the World Health Organization, many hospitals and healthcare facilities began to limit the number of elective procedures, including cancer screenings, in order to decrease risk of transmission of the virus and conserve healthcare resources. Therefore, breast cancer screenings were delayed or cancelled for many patients throughout the United States [1] . A study at a large healthcare provider group in Massachusetts also noted a decline in breast biopsies during the early months of the pandemic [1] . Postponing breast cancer screening and diagnostic procedures can lead to delayed cancer diagnoses, with reports of up to a 51.8% decreased incidence of new breast cancer diagnoses during the pandemic [2] .

In December 2020, the US Food and Drug Administration (FDA) authorized emergency use of two mRNA COVID-19 vaccines, Moderna and Pfizer-BioNTech. In February 2021, the Johnson & Johnson/Janssen adenovirus-based vaccine was also authorized for emergency use. This represents a necessary step towards reducing COVID-19 morbidity and mortality and allowing healthcare facilities to return to normal operations. As vaccination efforts increase, it is important for providers to be aware of potential side effects including the potential for axillary swelling/tenderness and adenopathy which have been reported with both mRNA vaccines and can present on routine breast imaging.

During the Moderna clinical trials, axillary swelling or tenderness was reported in up to 11.6% of patients following dose 1 and 16.0% of patients following dose 2 [3] . Furthermore, axillary and/or cervical lymphadenopathy was reported in 1.1% of patients 2 to 4 days after vaccination versus 0.6% in the placebo group [3] . The average duration of lymphadenopathy was 1 to 2 days [3] .

During the Pfizer-BioNTech clinical trials, vaccinated patients reported an increased incidence of axillary and/or cervical lymphadenopathy was reported as an unsolicited adverse event in 64 J o u r n a l P r e -p r o o f Journal Pre-proof of the vaccinated patients (<1%) with average duration of lymphadenopathy approximately 10 days [4] . Although, since lymphadenopathy was only reported as an unsolicited event in the clinical trials, the incidence rate is likely higher.

Axillary adenopathy in the setting of recent vaccination is not a new phenomenon. For example, there have been documented cases of ipsilateral axillary adenopathy following vaccination for BCG and influenza [5, 6] .

Since March 2021, there have been multiple articles discussing ipsilateral axillary adenopathy following COVID-19 vaccination (specifically the mRNA vaccines), including a case series from an institution in New York reporting 4 cases of unilateral axillary lymphadenopathy following COVID-19 vaccination in the ipsilateral arm, although no interval follow-up had been reported at time of publication [7] . There have also been reports on multiple online physician and breast radiology forums, including the Society for Breast Imaging and the American College of Radiology, of either personal experiences or seeing an increased number of imaging cases of ipsilateral axillary adenopathy following COVID-19 vaccination.

The Society of Breast Imaging (SBI) released guidelines for the management of axillary adenopathy in patients with recent COVID-19 vaccination. SBI recommends that unilateral axillary adenopathy on screening mammography be assigned BI-RADS 0 to further assess the ipsilateral breast and document vaccination history [8] . Following appropriate diagnostic work up in women who received the COVID-19 vaccine in the ipsilateral arm in the preceding four weeks, short term follow-up in 4-12 weeks after the second vaccine dose may be considered. breast imaging, as an incidental finding on diagnostic exams, or on targeted diagnostic workup as a response to direct complaint from the patient. Thus, radiologists must consider this etiology for unilateral axillary adenopathy across all patients, and not just those who present with clinical complaint of axillary pain or palpable abnormality. Current recommendations suggest obtaining COVID-19 vaccination history at the time of exam [8] , and as more of the population becomes vaccinated it is prudent to adopt this as a routine measure for any patient presenting for breast imaging.

Ultrasound appearance of the lymph nodes varied across our patients. Cases 2 and 4 demonstrated lymph node enlargement as well as a thickened cortex. Case 3 demonstrated unusual appearance of a heterogenous, hyperechoic, thickened cortex. It is unclear whether these differences in appearance have any clinical implications, and thus follow up imaging is appropriate in all cases to document resolution and exclude malignant etiology.

It is also worth noting that the axillary adenopathy was detected greater than 2-3 weeks following vaccination in cases 1 and 4. This is longer than the reported average duration of adenopathy in the Moderna and Pfizer-BioNTech clinical trials [3, 4] . This suggests that adenopathy may persist for two or more weeks following vaccination, and it is important for radiologists to recognize the possibility of this extended duration when considering the patient's history and making decisions about appropriate follow up. For the cases presented, short term imaging follow-up was recommended to ensure resolution of axillary adenopathy, with the exception of case 1 which recommended comparison to outside imaging.

Due to the COVID-19 pandemic, nearly all imaging centers have implemented new practice 

Abstract S11-03: Impact of COVID-19 on breast and prostate cancer screening and early detection in a large health care provider group

Changes in the Number of US Patients With Newly Identified Cancer Before and During the Coronavirus Disease

Systemic Reactions, Adverse Events, and Serious Adverse Events: Moderna COVID-19 Vaccine

Local Reactions

Axillary lymph node accumulation on FDG-PET/CT after influenza vaccination

Unilateral axillary Adenopathy in the setting of COVID-19 vaccine

SBI Recommendations for the Management of Axillary Adenopathy in Patients with Recent COVID-19 Vaccination

Mitigating the Impact of Coronavirus Disease (COVID-19) Vaccinations on Patients Undergoing Breast Imaging Examinations: A Pragmatic Approach

The Impact of the COVID-19 Pandemic on Breast Imaging

 Figure 1 . A 50 year old female presented with unilateral right axillary adenopathy on screening